Abstract
Virus-like particles hold great promise for the development of effective and affordable vaccines. Indeed, virus-like particles are suitable for presentation and efficient delivery of linear as well as conformational antigens to antigen-presenting cells. This will ultimately result in optimal B-cell activation and cross-presentation with both MHC class I and II molecules to prime CD4(+) T-helper as well as CD8(+) cytotoxic T cells. This article provides an update on the development and use of virus-like particles as vaccine approaches for infectious diseases and cancer.
MeSH terms
-
B-Lymphocytes / immunology
-
CD4-Positive T-Lymphocytes / immunology
-
CD8-Positive T-Lymphocytes / immunology
-
Cancer Vaccines / administration & dosage*
-
Cancer Vaccines / immunology*
-
Clinical Trials as Topic
-
Epitopes / immunology
-
Humans
-
Neoplasms / prevention & control
-
Neoplasms / therapy
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology
-
Vaccines, Virosome / administration & dosage
-
Vaccines, Virosome / immunology
-
Viral Vaccines / administration & dosage*
-
Viral Vaccines / immunology*
-
Virus Diseases / prevention & control
-
Virus Diseases / therapy
-
Viruses
Substances
-
Cancer Vaccines
-
Epitopes
-
Vaccines, Synthetic
-
Vaccines, Virosome
-
Viral Vaccines